biostudies-literatureUnknown7(10)Andres-Rozas M<h4>Background & aims</h4>Steatotic liver disease can lead to the development of metabolic dysfunction-associated steatohepatitis (MASH), the prevalence of which is rapidly increasing, intensifying the need to find an effective treatment. GTX-11 is a first-in-class drug with anti-inflammatory and antifibrotic properties mediated by the modulation of the transforming growth factor beta pathway. The present study evaluated the effects of GTX-11 on hepatic hemodynamics and liver fibrosis, as well as its underlying mechanisms, in a preclinical model of MASH, and in human precision-cut liver slices (hPCLS).<h4>Methods</h4>Male Wistar MASH rats received GTX-11 (1 and 10 mg/kg/day) or vehicle, for 14 days (n = 15/group). <i>In vivo</i> systemic and hepatic hemodynamics, fibrosis, biochemical paraJHEP reports : innovation in hepatology101497https://www.ebi.ac.uk/biostudies/studies/S-EPMC12447985biostudies-literatureGTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH.PMC12447985Guixe-Muntet SBoyer-Diaz ZGarcia-Delgado NLozano JJAristu-Zabalza PFuster CGracia-Sancho JAndres-Rozas MRuiz-Canovas EMercade JFernandez-Asensio CBosch JfalseGTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH.<h4>Background & aims</h4>Steatotic liver disease can lead to the development of metabolic dysfunction-associated steatohepatitis (MASH), the prevalence of which is rapidly increasing, intensifying the need to find an effective treatment. GTX-11 is a first-in-class drug with anti-inflammatory and antifibrotic properties mediated by the modulation of the transforming growth factor beta pathway. The present study evaluated the effects of GTX-11 on hepatic hemodynamics and liver fibrosis, as well as its underlying mechanisms, in a preclinical model of MASH, and in human precision-cut liver slices (hPCLS).<h4>Methods</h4>Male Wistar MASH rats received GTX-11 (1 and 10 mg/kg/day) or vehicle, for 14 days (n = 15/group). <i>In vivo</i> systemic and hepatic hemodynamics, fibrosis, biochemical para2025-01-01T00:00:00Z2025 Oct2026-06-03T17:02:00.402Z2026-05-30T03:06:23.243ZS-EPMC124479854098016010.1016/j.jhepr.2025.101497